Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease

Maintaining consistent levodopa benefits while simultaneously controlling dyskinesia can be difficult. Recently, an amantadine delayed release/extended release (DR/ER) formulation (Gocovri(®)) indicated for dyskinesia received additional FDA approval as an adjunct to levodopa for the treatment of OF...

Descripción completa

Detalles Bibliográficos
Autores principales: Hauser, Robert A., Lytle, Judy, Formella, Andrea E., Tanner, Caroline M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933492/
https://www.ncbi.nlm.nih.gov/pubmed/35304480
http://dx.doi.org/10.1038/s41531-022-00291-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933492/
https://www.ncbi.nlm.nih.gov/pubmed/35304480
http://dx.doi.org/10.1038/s41531-022-00291-1

Ejemplares similares